Navigation Links
Inovio Biomedical Highlights Enhanced DNA Vaccine Potency with,Electroporation DNA Delivery Technology and New Devices at Gene,Therapy Meeting

nd demonstrated that the electroporation-enhanced immune responses to a hepatitis C DNA vaccine were capable of eliminating all liver cells that produced a model hepatitis C virus gene, simulating a potential cure of hepatitis C infection. Vaccination by methods not employing Inovio's technology were less or not effective.

Two other Inovio presentations reported electroporation device innovations including the Elgen 1000 system and a single-needle device. The Elgen 1000 system, which recently received CE marking, consists of an advanced pulse generator and a two-needle DNA injector that delivers the genes and electroporation pulses in a single step. The pulse generator allows flexible programming of pulse and injection parameters via a flash card operated personal computer, as well as comprehensive recording and storage of electroporation and patient data. The single needle device, in early development, allows injection of the DNA and electroporation with a single needle resembling a normal injection needle and applies pulses of lower voltage than those delivered by presently used devices, thus reducing the electrical sensation experienced by the patient.

"We are pleased with the performance of our DNA delivery technology in advanced preclinical studies. Together with our continuing innovations in electroporation devices, our technology may be able to make critical contributions to the development of novel, effective vaccines for the treatment or prevention of major life-threatening infectious diseases," said Dr. Avtar Dhillon, Inovio's president and CEO.

About Inovio's Immunotherapy Products

DNA-based immunotherapy products have the potential to by-pass inherent scientific obstacles of conventional vaccines that prevent their development for cancer and chronic infectious diseases such as HIV and hepatitis C. Pre-clinical data has indicated the potential ability of Inovio's technologies to safely and effectively deliver and significantly
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Vical Interim Clinical Results Demonstrate Safety and Tolerability of Inovio Biomedicals Electroporation DNA Delivery Technology
2. Inovio Biomedicals DNA Delivery Technology Shows Safety and Enhances Gene Expression & Tumor Responses in Interim Melanoma Clinical Study Results
3. Inovio: DNA delivery technology shows positive human results
4. Inovio Biomedicals Partners to Present New Data from Two Cancer Immunotherapy Clinical Trials
5. Inovio Biomedicals DNA Delivery Technology Significantly Enhances Potency of HIV DNA Vaccine
6. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
7. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
8. Expert Opinion Highlights Avigens AV411 as Potential New Therapeutic for Neuropathic Pain and Opioid Withdrawal
9. Positive Clinical Results for DG041 Lead Product Development Highlights at deCODE R&D Event
10. Ambrilia Highlights Encouraging Data for its HIV Integrase Inhibitor Program and Recent Developments at Annual Meeting
11. July Issue of Journal of Antimicrobial Chemotherapy Highlights Study of Factive Tablets for Five-Day Treatment of Community-Acquired Pneumonia
Post Your Comments:
(Date:9/18/2014)... , Sept. 18, 2014  Iliad Neurosciences, Inc., a ... diagnosing and treating Autism Spectrum Disorders (ASD) announced today ... with The Research Foundation for The State University of ... provide a new biomarker to identify an abnormality in ... ASD. This biomarker is expected to be available for ...
(Date:9/18/2014)... , Sept. 18, 2014  ePharmaSolutions, ... was recognized as the Disruptive Innovator of ... ePharmaONE cloud-based eClinical platform. This solution includes ... trial master file (eTMF), a remote monitoring ... ePharmaSolutions, ReferralPlus+ patient screening and matching technology. ...
(Date:9/18/2014)... PLAINSBORO, N.J. , Sept. 18, ... of the National Hemophilia Foundation,s (NHF) new three-year ... support to people with hemophilia and their families/caregivers ... that can impede disease management. The curriculum for ... With Your Provider About Pain , focuses on ...
Breaking Medicine Technology:Iliad Neurosciences, Inc. enters into an Exclusive License Agreement with The Research Foundation for The State University of New York 2Iliad Neurosciences, Inc. enters into an Exclusive License Agreement with The Research Foundation for The State University of New York 3ePharmaSolutions Named 2014 Disruptive Innovator of the Year for its ePharmaONE eClinical Platform 2ePharmaSolutions Named 2014 Disruptive Innovator of the Year for its ePharmaONE eClinical Platform 3Novo Nordisk Supports National Hemophilia Foundation Initiative for "Collaborating in Care" Disease Management Program 2Novo Nordisk Supports National Hemophilia Foundation Initiative for "Collaborating in Care" Disease Management Program 3
... 1 RX-3341 Results -, NEW HAVEN, Conn., ... "Company"), a development-stage company focused on the,discovery and ... infections, today announced the initiation of a Phase,2 ... compound RX-3341 in,the treatment of complicated skin and ...
... Will Remain as the Clinical Gold Standard ... New Report from Decision Resources, WALTHAM, Mass., ... leading research and advisory firms focusing on pharmaceutical ... in preventing,recurrence of depressive mood episodes in patients ...
Cached Medicine Technology:Rib-X Pharmaceuticals Initiates Phase 2 Trial for RX-3341 In Complicated Skin and Skin Structure Infections 2Rib-X Pharmaceuticals Initiates Phase 2 Trial for RX-3341 In Complicated Skin and Skin Structure Infections 3Current and Emerging Drugs Continue to Struggle for Patient Share in the Treatment of Major Depressive Disorder 2
(Date:9/19/2014)... 19, 2014 VogueQueen.com has ... that will make ladies more beautiful at their weddings. ... everyone can afford. The company’s new products are made ... offering great savings for all the global clients. ... extremely beautiful. I have ordered several items on its ...
(Date:9/18/2014)... (PRWEB) September 18, 2014 Defendants ... http://www.xareltolawsuitcenter.com ) currently pending in Pennsylvania’s Philadelphia Court ... claims filed on behalf of out-of-state plaintiffs dismissed, ... on September 11th, the defendants maintain that circumstances ... in the lawsuits have no connection to Pennsylvania. ...
(Date:9/18/2014)... 2014 Dr. David A. F. Ellis ... American Academy of Facial Plastic and Reconstructive Surgery and ... Division of Facial Plastic Surgery. He is recognized ... surgery. , Dr. Ellis will be presenting on ... presenting on injection techniques and various treatments for complications ...
(Date:9/18/2014)... to diverse communities may boost infants, social learning, according ... in the park or supermarket could help children be ... different from them, researchers found. "Research has ... interacting with and learning from people who are different ... psychology professor, said in a university news release. ...
(Date:9/18/2014)... (PRWEB) September 18, 2014 "Medical staff ... care while also maintaining the patient's privacy," said one ... with this idea in order to supply caregivers with ... , They created a prototype for The Helper to ... enables staff to turn patient onto his or her ...
Breaking Medicine News(10 mins):Health News:VogueQueen.com’s New Line Of Cheap Wedding Dresses Aims To Attract Chic Ladies 2Health News:Xarelto Lawsuit Defendants Seek to Have Pennsylvania Claims Filed by Out-of-State Plaintiffs Dismissed, Bernstein Liebhard LLP Reports 2Health News:Xarelto Lawsuit Defendants Seek to Have Pennsylvania Claims Filed by Out-of-State Plaintiffs Dismissed, Bernstein Liebhard LLP Reports 3Health News:Dr. David A. F. Ellis Has Been Invited to Speak at a Conference of the American Academy of Facial Plastic and Reconstructive Surgery in Orlando, Florida 2Health News:Study: Exposure to Diversity Might Boost Baby's Social Skills 2
... , RE: American Psychological Association 116th Annual Convention in ... 162A, Meeting Level 1, Boston Convention and Exhibition Center. ... tops and two high-speed printers. We will also provide ... transmission and APA staff resources. This room will also ...
... Joel Ario today announced that the Insurance Department ... the state to,hear from consumers and other affected ... and Independence Blue Cross, plus related,changes, will impact ... held July 8 in Pittsburgh, July 10 in ...
... Officials Not to Privatize,Veterans, Health Care, WASHINGTON, ... today launched a nationwide radio ad campaign,urging Congress ... of,Veterans, Affairs. In the ad, AFGE urges presidential ... for the VA., "As the nation,s highest ...
... release is available in French . , Montreal, ... traumatic experience and, in some cases, emotional and physical pain ... phantom limb syndrome, Universit de Montral graduate student Emma Duerden ... for a major study. , Our main goal is to ...
... of cancers that affect tissues such as muscle, fat, ... Italy on 13-14 May to discuss the latest information ... for therapy. , The 2nd Symposium on Sarcoma and ... for Medical Oncology (ESMO), will include sessions on the ...
... International Inc., found to have committed patent and ... ... Mannatech,Incorporated (Nasdaq: MTEX ) a leading developer and provider ... federal court,jury in the Northern District of Texas found that ...
Cached Medicine News:Health News:Highlights for APA's 116th Annual Convention in Boston, Aug. 14-17 2Health News:Highlights for APA's 116th Annual Convention in Boston, Aug. 14-17 3Health News:Highlights for APA's 116th Annual Convention in Boston, Aug. 14-17 4Health News:Insurance Department to Hold Statewide Meetings on Proposed Consolidation of Independence Blue Cross, Highmark 2Health News:AFGE Launches Nationwide Ad Campaign Aimed at Funding the VA 2Health News:2nd ESMO symposium on soft tissue carcinomas and GIST 2Health News:2nd ESMO symposium on soft tissue carcinomas and GIST 3Health News:Jury Validates Key Mannatech Technology Patents Involving Its Ambrotose(R) Glyconutrient Products 2Health News:Jury Validates Key Mannatech Technology Patents Involving Its Ambrotose(R) Glyconutrient Products 3
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: